AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

November 27, 2019 GMT

NEW YORK--(BUSINESS WIRE)--Nov 27, 2019--

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces participation at the following upcoming conferences:

  • Evercore ISI 2 nd Annual HealthCONx Conference
    • Gaurav Shah, M.D., President and CEO, is scheduled to present on Tuesday, December 3, 2019, at 11:20 a.m. Eastern Time.
  • Piper Jaffray’s 31 st Annual Healthcare Conference
    • Gaurav Shah, M.D., President and CEO, is scheduled to present on Thursday, December 5, 2019, at 1:00 p.m. Eastern Time.

A live audio webcast of the presentations will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentations will be archived on the Rocket website following the conferences.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients contending with rare genetic diseases. Rocket’s clinical programs using LVV-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rocket’s first clinical program using AAV-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Rocket’s pre-clinical pipeline program is for Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. For more information about Rocket, please visit www.rocketpharma.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191127005155/en/

CONTACT: Claudine Prowse, Ph.D.

SVP, Strategy & Corporate Development

investors@rocketpharma.com

KEYWORD: UNITED STATES NORTH AMERICA NEW YORK

INDUSTRY KEYWORD: HEALTH STEM CELLS GENETICS PHARMACEUTICAL CARDIOLOGY BIOTECHNOLOGY

SOURCE: Rocket Pharmaceuticals, Inc.

Copyright Business Wire 2019.

PUB: 11/27/2019 07:00 AM/DISC: 11/27/2019 07:01 AM

http://www.businesswire.com/news/home/20191127005155/en